Latanoprost

Latanoprost Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 38 adverse event reports referencing Latanoprost, including 4 reports in which the animal died — a 1050.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Latanoprost. Reported administration routes include Ophthalmic, Unknown, Other, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Latanoprost reports are Dog (32 reports), Cat (3 reports), Unknown (2 reports), with Dog accounting for the largest share. Within those species, Shih Tzu (6), Unknown (3), Crossbred Canine/dog (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Latanoprost are Vomiting (6), Lack of efficacy - NOS (6), Eye disorder NOS (for photophobia see 'neurological') (5), Lethargy (see also Central nervous system depression in 'Neurological') (5). Of the 36 reports with a coded outcome, Recovered/Normal is the leading category at 38.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Latanoprost.